Stockscreener 앱 받기
7.38
2.12%
-0.16
시간 외 거래:
7.69
0.31
+4.20%
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus (CRBP) Chief Business Officer buys 13,500 shares in open market - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals targets HPV-linked head and neck cancer with CRB-701 study - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study - Yahoo Finance
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price Today & Analysis - Gotrade
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP Q1 2026 Earnings: Narrower Loss Misses on Thin Volume; No Revenue YetWeak Earnings Momentum - thelegaladvocate.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Why (CRBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
TNXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
CRBP Maintained by Wedbush -- Price Target Lowered to $30 - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop (NASDAQ:CRBP) - Seeking Alpha
LifeSci Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Wedbush Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
Corbus Pharmaceuticals (CRBP) Is Down 19.6% After FDA Aligns On CRB-701 Registrational StrategyHas The Bull Case Changed? - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study - Moomoo
Corbus Pharmaceuticals (CRBP) Analyst Sees Mispriced Weakness - GuruFocus
Corbus Pharmaceuticals (CRBP) Reports Promising Data on CRB-701 Trial - GuruFocus
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
CRBP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CRB-701 Phase 1/2 data outlines next steps, Corbus Pharmaceuticals Holdings, Inc. - Traders Union
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCOSlideshow (NASDAQ:CRBP) 2026-05-26 - Seeking Alpha
Corbus Pharmaceuticals stock falls on trial data release By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals stock falls on trial data release - Investing.com
CRB-701 data advances Corbus (NASDAQ: CRBP) OPSCC and cervical plans - Stock Titan
Corbus slips after updated trial data for cancer candidate - Seeking Alpha
Corbus Pharmaceuticals Holdings Inc Pre-2026 ASCO Conference Call Transcript - GuruFocus
CRBP: CRB-701 and CRB-913 delivered promising efficacy and safety in cancer and obesity studies - TradingView
Mizuho raises Corbus Pharmaceuticals stock price target to $44 on ASCO data confidence - Investing.com Canada
CRBP: CRB-701 demonstrates strong efficacy and safety in 2L OPSCC and cervical cancer, with registrational trials planned - TradingView
Corbus Pharmaceuticals reports updated CRB-701 phase 1/2 clinical data demonstrating robust activity in 2L oropharyngeal and cervical cancers - marketscreener.com
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers - The Norfolk Daily News
Corbus Pharmaceuticals Q1 2026 Earnings: Smaller-Than-Expected Loss Amid Pipeline ProgressCFO Commentary Report - thelegaladvocate.com
Corbus Pharmaceuticals teases key ASCO cancer data, late-summer obesity readout - MSN
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Raises Target Price to $44 - Moomoo
CRBP Maintained by Mizuho -- Price Target Raised to $44.00 - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus (CRBP) Chief Business Officer receives RSUs and 192,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) CBO Nishant Saxena reports holding 3,500 shares - Stock Titan
Corbus Pharmaceuticals Is Maintained at Outperform by Mizuho - Moomoo
Colliers facilitates 36,471 s/f lease renewal for Corbus Pharmaceuticals - NEREJ
Mizuho raises Corbus Pharmaceuticals stock price target on ASCO preview By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - Sahm
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout - TradingView
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxen - The National Law Review
1.59%
0.77%
자본화:
|
볼륨(24시간):